<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192139</url>
  </required_header>
  <id_info>
    <org_study_id>CV181-111</org_study_id>
    <nct_id>NCT01192139</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)</brief_title>
  <official_title>Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN) Coadministered to Healthy Subjects in a Fed Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate bioequivalence (BE) of a 5 mg saxagliptin/500 mg
      metformin extended release (XR) fixed-dose combination (FDC) tablet (manufactured in Mt
      Vernon, Indiana [IN]) to coadministered 5 mg saxagliptin and 500 mg metformin XR tablet
      (manufactured in Evansville, IN) in fed healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate if the FDC tablet of 5 mg saxagliptin/500 mg metformin
      extended release (manufactured in Mt Vernon, Indiana) is bioequivalent to the coadministered
      5 mg saxagliptin and 500 mg metformin XR tablet (manufactured in Evansville, Indiana)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</measure>
    <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t [calculated using the linear trapezoidal rule] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Saxagliptin Observed Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin AUC(0-inf)</measure>
    <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t [calculated using the linear trapezoidal rule] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metformin Cmax</measure>
    <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Saxagliptin Terminal Half-life (T1/2)</measure>
    <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
    <description>terminal half life; calculated as ln(2)/Kel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])</measure>
    <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve the Observed Maximum Saxagliptin Plasma Concentration (Tmax)</measure>
    <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])</measure>
    <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active Metabolite BMS-510849 AUC(0-inf)</measure>
    <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t [calculated using the linear trapezoidal rule] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active Metabolite BMS-510849 AUC(0-t)</measure>
    <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active Metabolite BMS-510849 Cmax</measure>
    <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active Metabolite BMS-510849 T1/2</measure>
    <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
    <description>terminal half life; calculated as ln(2)/Kel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active Metabolite BMS-510849 Tmax</measure>
    <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active Metabolite BMS-510849 AUC(0-t)/AUC(0-inf)</measure>
    <time_frame>Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin AUC(0-t)</measure>
    <time_frame>Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin T1/2</measure>
    <time_frame>Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)</time_frame>
    <description>terminal half life; calculated as ln(2)/Kel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin Tmax</measure>
    <time_frame>Periods 1, 2, and 3 (before dosing, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin Fraction of AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])</measure>
    <time_frame>Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)</measure>
    <time_frame>AEs: from initiation of study drug administration on Day 1/Period 1 through study discharge Day 3/Period 3. SAEs: from date of written consent until 30 days after discontinuation of dosing or participation in study if last scheduled visit occurred later.</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>From Day 1 of Period 1 through Day 3 of Period 3 (study discharge)</time_frame>
    <description>Abnormalities considered by the investigator to be clinically significant and/or reported as an AE.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>5 mg saxagliptin + a single 500 mg metformin XR tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>under fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fasting)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>under fasted state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saxagliptin</intervention_name>
    <description>Tablets, Oral, 5 mg, once daily, Single dose</description>
    <arm_group_label>5 mg saxagliptin + a single 500 mg metformin XR tablet</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin XR</intervention_name>
    <description>Tablets, Oral, 500 mg. once daily, Single dose</description>
    <arm_group_label>5 mg saxagliptin + a single 500 mg metformin XR tablet</arm_group_label>
    <other_name>Glucophage XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saxagliptin + metformin XR (FDC tablet)</intervention_name>
    <description>Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose</description>
    <arm_group_label>FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fed)</arm_group_label>
    <arm_group_label>FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fasting)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects as determined by no clinically significant deviation
             from normal in medical history, physical examination, electrocardiogram (ECG), and
             clinical laboratory determinations

          -  Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive

          -  Ages 18 to 45, inclusive

        Exclusion Criteria:

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG or clinical laboratory determinations beyond
             what is consistent with the target population

          -  Major surgical procedure within 4 weeks prior to randomization

          -  Positive serology test for human immunodeficiency virus (HIV), hepatitis B virus (HBV)
             or hepatitis C virus (HCV)

          -  Clinically significant history or presence of any of the following conditions: heart,
             liver, or kidney disease, neurologic or psychiatric disease

          -  History of gastrointestinal disease within the past 3 months

          -  Any clinically significant medical condition that could potentially affect your
             participation in the study and/or personal well-being, as judged by the investigator

          -  Donated blood or blood products to a blood bank, blood transfusion or participated in
             a clinical study (except a screening visit) requiring withdrawal of blood within 4
             weeks prior to randomization

          -  Unable to tolerate oral and/or intravenous (IV) medications

          -  Unable to tolerate the puncturing of veins for drawing of blood

          -  Known allergy or hypersensitivity to any component of the study medication

          -  History of any significant drug allergies (such as anaphylaxis or hepatotoxicity)

          -  Used any prescription drugs or over the counter products to control acid (for example,
             Prevacid, Mylanta or Rolaids) within 4 weeks prior to randomization

          -  Used any other drugs including over the counter medications and herbal preparations
             within 1 week prior to randomization

          -  Taken any investigational drug or placebo (inactive drug) within 4 weeks prior to
             randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ppd Development, Lp</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2010</study_first_posted>
  <results_first_submitted>March 11, 2011</results_first_submitted>
  <results_first_submitted_qc>April 19, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 17, 2011</results_first_posted>
  <last_update_submitted>May 4, 2015</last_update_submitted>
  <last_update_submitted_qc>May 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants underwent screening evaluations to determine eligibility within 21 days before dosing, and were admitted to the clinical facility the evening before dosing (Day â€“1). On Day 1 of Period 1, a total of 30 participants who met all of the inclusion and none of the exclusion criteria were randomly assigned to 1 of 6 treatment sequences.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence ABC</title>
          <description>Treatment A (period 1): 5 mg saxagliptin + a single 500 mg metformin XR tablet; Treatment B (period 2): fixed-dose combination (FDC) Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions; Treatment C (period 3): FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions. Participants underwent at least a 3-day washout period between each treatment.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence ACB</title>
          <description>Treatment A (period 1): 5 mg saxagliptin + a single 500 mg metformin XR tablet; Treatment C (period 2): FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions; Treatment B (period 3): fixed-dose combination (FDC) Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions. Participants underwent at least a 3-day washout period between each treatment.</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence BAC</title>
          <description>Treatment B (period 1): fixed-dose combination (FDC) Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions; Treatment A (period 2): 5 mg saxagliptin + a single 500 mg metformin XR tablet; Treatment C (period 3): FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions. Participants underwent at least a 3-day washout period between each treatment.</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence BCA</title>
          <description>Treatment B (period 1): fixed-dose combination (FDC) Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions; Treatment C (period 2): FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions; Treatment A (period 3): 5 mg saxagliptin + a single 500 mg metformin XR tablet. Participants underwent at least a 3-day washout period between each treatment.</description>
        </group>
        <group group_id="P5">
          <title>Treatment Sequence CAB</title>
          <description>Treatment C (period 1): FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions; Treatment A (period 2): 5 mg saxagliptin + a single 500 mg metformin XR tablet; Treatment B (period 3): fixed-dose combination (FDC) Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions. Participants underwent at least a 3-day washout period between each treatment.</description>
        </group>
        <group group_id="P6">
          <title>Treatment Sequence CBA</title>
          <description>Treatment C (period 1): FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions; Treatment B (period 2): fixed-dose combination (FDC) Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions; Treatment A (period 3): 5 mg saxagliptin + a single 500 mg metformin XR tablet. Participants underwent at least a 3-day washout period between each treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Enrolled and Treated Participants</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.0" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.31" spread="13.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.97" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</title>
        <description>Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t [calculated using the linear trapezoidal rule] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant</description>
        <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])</title>
          <description>Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t [calculated using the linear trapezoidal rule] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant</description>
          <population>All treated participants</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.28" spread="25.13"/>
                    <measurement group_id="O2" value="111.72" spread="26.55"/>
                    <measurement group_id="O3" value="103.35" spread="23.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of a saxagliptin tablet and a metformin XR tablet under fed conditions, then 24 subjects would have provided 99% power to conclude bioequivalence (BE) with respect to Cmax and AUC0-inf. If there was a 5% difference, then 24 subjects would have provided 94% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>BE was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within 0.800 to 1.250 for both Cmax and AUC0-inf of saxagliptin</non_inferiority_desc>
            <param_type>Ratio of Geometric Least Squares Means</param_type>
            <param_value>1.039</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.011</ci_lower_limit>
            <ci_upper_limit>1.068</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lack of food effect was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within (80%, 125%) for both Cmax and AUC(INF) of saxagliptin and metformin.</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>1.078</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.049</ci_lower_limit>
            <ci_upper_limit>1.108</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for treatment A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>104.65</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for treatment B</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>108.74</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for treatment C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>100.84</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saxagliptin Terminal Half-life (T1/2)</title>
        <description>terminal half life; calculated as ln(2)/Kel</description>
        <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Saxagliptin Terminal Half-life (T1/2)</title>
          <description>terminal half life; calculated as ln(2)/Kel</description>
          <population>All treated participants</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.46" spread="2.85"/>
                    <measurement group_id="O2" value="8.56" spread="3.04"/>
                    <measurement group_id="O3" value="9.21" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])</title>
        <description>Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.</description>
        <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])</title>
          <description>Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.</description>
          <population>All treated participants</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.47" spread="24.98"/>
                    <measurement group_id="O2" value="109.88" spread="26.36"/>
                    <measurement group_id="O3" value="101.52" spread="23.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Least Squares Mean</param_type>
            <param_value>1.039</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.011</ci_lower_limit>
            <ci_upper_limit>1.068</ci_upper_limit>
            <estimate_desc>Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Least Squares Means</param_type>
            <param_value>1.080</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.051</ci_lower_limit>
            <ci_upper_limit>1.110</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for treatment A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>102.84</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for treatment B</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>106.89</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for treatment C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>98.99</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Saxagliptin Observed Maximum Plasma Concentration (Cmax)</title>
        <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Saxagliptin Observed Maximum Plasma Concentration (Cmax)</title>
          <population>All treated participants</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.84" spread="8.26"/>
                    <measurement group_id="O2" value="27.25" spread="7.95"/>
                    <measurement group_id="O3" value="28.85" spread="8.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of a saxagliptin tablet and a metformin XR tablet under fed conditions, then 24 subjects would have provided 99% power to conclude bioequivalence (BE) with respect to Cmax and AUC0-inf. If there was a 5% difference, then 24 subjects would have provided 94% and 99% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>BE was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within 0.800 to 1.250 for both Cmax and AUC0-inf of saxagliptin.</non_inferiority_desc>
            <param_type>Ratio of Geometric Least Squares Means</param_type>
            <param_value>1.021</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.940</ci_lower_limit>
            <ci_upper_limit>1.109</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lack of food effect was concluded if the fed to fasted ratios of geometric means were entirely contained within (80%, 125%) for both Cmax and AUC(INF) of saxagliptin.</non_inferiority_desc>
            <param_type>Ratio of Geometric Least Squares Means</param_type>
            <param_value>0.949</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.873</ci_lower_limit>
            <ci_upper_limit>1.031</ci_upper_limit>
            <estimate_desc>Ratio = Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for treatment A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>25.68</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for treatment B</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>26.21</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for treatment C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>27.63</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve the Observed Maximum Saxagliptin Plasma Concentration (Tmax)</title>
        <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve the Observed Maximum Saxagliptin Plasma Concentration (Tmax)</title>
          <population>All treated participants</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.65"/>
                    <measurement group_id="O2" value="1.48" spread="0.75"/>
                    <measurement group_id="O3" value="0.65" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])</title>
        <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])</title>
          <population>All treated participants</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.983" spread="0.006"/>
                    <measurement group_id="O2" value="0.983" spread="0.006"/>
                    <measurement group_id="O3" value="0.982" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Metabolite BMS-510849 AUC(0-inf)</title>
        <description>Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t [calculated using the linear trapezoidal rule] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant</description>
        <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Active Metabolite BMS-510849 AUC(0-inf)</title>
          <description>Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t [calculated using the linear trapezoidal rule] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant</description>
          <population>All treated participants</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.72" spread="79.21"/>
                    <measurement group_id="O2" value="295.94" spread="75.40"/>
                    <measurement group_id="O3" value="289.06" spread="66.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Metabolite BMS-510849 AUC(0-t)</title>
        <description>Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.</description>
        <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Active Metabolite BMS-510849 AUC(0-t)</title>
          <description>Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.</description>
          <population>All treated participants</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284.46" spread="78.25"/>
                    <measurement group_id="O2" value="289.03" spread="74.80"/>
                    <measurement group_id="O3" value="281.79" spread="65.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Metabolite BMS-510849 Cmax</title>
        <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Active Metabolite BMS-510849 Cmax</title>
          <population>All treated participants</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.71" spread="16.94"/>
                    <measurement group_id="O2" value="49.28" spread="14.59"/>
                    <measurement group_id="O3" value="49.09" spread="15.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Metabolite BMS-510849 T1/2</title>
        <description>terminal half life; calculated as ln(2)/Kel</description>
        <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Active Metabolite BMS-510849 T1/2</title>
          <description>terminal half life; calculated as ln(2)/Kel</description>
          <population>All treated participants</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.88" spread="1.53"/>
                    <measurement group_id="O2" value="13.65" spread="1.72"/>
                    <measurement group_id="O3" value="14.04" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Metabolite BMS-510849 Tmax</title>
        <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Active Metabolite BMS-510849 Tmax</title>
          <population>All treated participants</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="0.76"/>
                    <measurement group_id="O2" value="2.42" spread="0.88"/>
                    <measurement group_id="O3" value="1.46" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Metabolite BMS-510849 AUC(0-t)/AUC(0-inf)</title>
        <time_frame>Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Active Metabolite BMS-510849 AUC(0-t)/AUC(0-inf)</title>
          <population>All treated participants</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.974" spread="0.008"/>
                    <measurement group_id="O2" value="0.975" spread="0.008"/>
                    <measurement group_id="O3" value="0.974" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metformin AUC(0-inf)</title>
        <description>Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t [calculated using the linear trapezoidal rule] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant</description>
        <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>Treated participants (the smaller sample size for AUC[0-inf] was due to the inability to estimate potassium chloride for some participants)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin AUC(0-inf)</title>
          <description>Area under the plasma concentration versus time curve from time 0 extrapolated to infinity; calculated as AUC0-t [calculated using the linear trapezoidal rule] + Ct/Kel, where Ct was the last measurable concentration and Kel was the terminal rate constant</description>
          <population>Treated participants (the smaller sample size for AUC[0-inf] was due to the inability to estimate potassium chloride for some participants)</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5865.92" spread="2357.15"/>
                    <measurement group_id="O2" value="5516.97" spread="2423.08"/>
                    <measurement group_id="O3" value="5073.70" spread="1406.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of a saxagliptin tablet and a metformin XR tablet under fed conditions, then 24 subjects would have provided 99% power to conclude BE with respect to Cmax and AUC0-inf. If there was a 5% difference, then 24 subjects would have provided 96% and 97% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>BE concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within (80%, 125%) for both Cmax and AUC(INF) of saxagliptin and metformin.</non_inferiority_desc>
            <param_type>Ratio of Least Squares Geometric Means</param_type>
            <param_value>0.915</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.836</ci_lower_limit>
            <ci_upper_limit>1.002</ci_upper_limit>
            <estimate_desc>Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>lack of food effect concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within (80%, 125%) for both Cmax and AUC(INF) of saxagliptin and metformin.</non_inferiority_desc>
            <param_type>Ratio of Geometric LS Mean and 90% CI</param_type>
            <param_value>1.010</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.918</ci_lower_limit>
            <ci_upper_limit>1.111</ci_upper_limit>
            <estimate_desc>Ratio = Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for treatment A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>5542.2</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for treatment B</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>5072.9</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for treatment C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>5023.3</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin AUC(0-t)</title>
        <description>Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.</description>
        <time_frame>Period 1 (samples taken before dosing, and at 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin AUC(0-t)</title>
          <description>Area under the plasma concentration versus time curve from time 0 to the time of the last quantifiable concentration (Ct), calculated using the linear trapezoidal rule.</description>
          <population>All treated participants</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5617.39" spread="2181.99"/>
                    <measurement group_id="O2" value="5200.46" spread="2203.34"/>
                    <measurement group_id="O3" value="4896.95" spread="1340.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Least Squares Mean</param_type>
            <param_value>0.920</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.854</ci_lower_limit>
            <ci_upper_limit>0.992</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of Geometric Least Squares Means</param_type>
            <param_value>1.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.951</ci_lower_limit>
            <ci_upper_limit>1.105</ci_upper_limit>
            <estimate_desc>Ratio=Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for treatment A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>5287.1</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for treatment B</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>4866.2</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares means for treatment C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>4746.8</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Metformin Cmax</title>
        <time_frame>Periods 1, 2, and 3 (samples taken before dosing, and at 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin Cmax</title>
          <population>All treated participants</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="629.73" spread="160.14"/>
                    <measurement group_id="O2" value="586.87" spread="150.63"/>
                    <measurement group_id="O3" value="657.23" spread="187.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of a metformin XR tablet under fed conditions, then 24 subjects would have provided 99% power to conclude BE with respect to Cmax and AUC0-inf. If there was a 5% difference, then 24 subjects would have provided 96% and 97% power to conclude BE with respect to Cmax and AUC0-inf, respectively.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>BE was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within 0.800 to 1.250 for both Cmax and AUC0-inf of metformin.</non_inferiority_desc>
            <param_type>Ratio of Geometric Least Squares Means</param_type>
            <param_value>0.933</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.865</ci_lower_limit>
            <ci_upper_limit>1.007</ci_upper_limit>
            <estimate_desc>Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Lack of food effect was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within (80%, 125%) for both Cmax and AUC(inf) of saxagliptin and metformin.</non_inferiority_desc>
            <param_type>Ratio of Geometric Least Squares Means</param_type>
            <param_value>0.898</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.832</ci_lower_limit>
            <ci_upper_limit>0.969</ci_upper_limit>
            <estimate_desc>Ration = Treatment B/Treatment C. Geometric least squares means values are presented in other statistical analysis entries.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for treatment A</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>608.41</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for treatment B</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>567.85</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Geometric least squares mean for treatment C</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Geometric least squares mean (ng*hr/mL)</param_type>
            <param_value>632.39</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin T1/2</title>
        <description>terminal half life; calculated as ln(2)/Kel</description>
        <time_frame>Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)</time_frame>
        <population>Treated participants (the smaller sample size for T1/2 was due to the inability to estimate Kel for some of the subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin T1/2</title>
          <description>terminal half life; calculated as ln(2)/Kel</description>
          <population>Treated participants (the smaller sample size for T1/2 was due to the inability to estimate Kel for some of the subjects).</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="5.90"/>
                    <measurement group_id="O2" value="12.6" spread="7.05"/>
                    <measurement group_id="O3" value="14.9" spread="7.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin Tmax</title>
        <time_frame>Periods 1, 2, and 3 (before dosing, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 18, 24, 36 and 48 hours after dosing)</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin Tmax</title>
          <population>All treated participants</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="1.04"/>
                    <measurement group_id="O2" value="4.90" spread="1.13"/>
                    <measurement group_id="O3" value="4.11" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metformin Fraction of AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])</title>
        <time_frame>Period 1 (before dosing, 0.167,0.25,0.5,0.75,1,1.5,2,3,4,5,6,7,8,10,12,18,24,36 and 48 hours after dosing)</time_frame>
        <population>Treated participants (the smaller sample size for AUC(0-inf) was due to the inability to estimate Kel for some of the subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Metformin Fraction of AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])</title>
          <population>Treated participants (the smaller sample size for AUC(0-inf) was due to the inability to estimate Kel for some of the subjects).</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.979" spread="0.020"/>
                    <measurement group_id="O2" value="0.970" spread="0.026"/>
                    <measurement group_id="O3" value="0.965" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.</description>
        <time_frame>AEs: from initiation of study drug administration on Day 1/Period 1 through study discharge Day 3/Period 3. SAEs: from date of written consent until 30 days after discontinuation of dosing or participation in study if last scheduled visit occurred later.</time_frame>
        <population>Safety Population = all participants who received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.</description>
          <population>Safety Population = all participants who received any study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Participants With At Least 1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Due to an AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and Electrocardiogram (ECG) Abnormalities</title>
        <description>Abnormalities considered by the investigator to be clinically significant and/or reported as an AE.</description>
        <time_frame>From Day 1 of Period 1 through Day 3 of Period 3 (study discharge)</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A - Saxagliptin + Metformin XR, Fed</title>
            <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
          </group>
          <group group_id="O2">
            <title>Treatment B - FDC Tablet (Saxagliptin + Metformin XR), Fed</title>
            <description>fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
          </group>
          <group group_id="O3">
            <title>Treatment C - FDC Tablet (Saxagliptin + Metformin XR), Fasting</title>
            <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and Electrocardiogram (ECG) Abnormalities</title>
          <description>Abnormalities considered by the investigator to be clinically significant and/or reported as an AE.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Laboratory Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vital Sign Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Examination Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Lead ECG Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>5 mg saxagliptin tablet + a single 500 mg metformin XR tablet under fed conditions</description>
        </group>
        <group group_id="E2">
          <title>Treatment C</title>
          <description>FDC Tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fasting conditions</description>
        </group>
        <group group_id="E3">
          <title>Treatment B</title>
          <description>Fixed-dose combination (FDC) tablet (5 mg Saxagliptin + 500 mg Metformin XR) under fed conditions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>CHAPPED LIPS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>LIP SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period â‰¤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boaz Hirschberg</name_or_title>
      <organization>AstraZeneca Pharmaceuticals</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

